查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466263

品牌非专利市场：按产品类型、药物类型、给药途径、适应症、分销管道 - 全球预测 2024-2030

Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年品牌非专利市场规模为4,323亿美元，预计2024年将达到4,942.9亿美元，2030年将达到11,264.3亿美元，复合年增长率为14.66%。

品牌学名药是指与品牌药在生物学上等效的药物，在专利到期后由另一家公司以不同的品牌名称销售。这些药物采用与原厂药相同的活性成分 (API) 配製，并且必须满足有关製造流程、安全性和功效标准的类似监管要求。然而，品牌非专利药与原厂药在辅料、包装材料、生产流程等方面可能存在细微差别。消费者对可及治疗方法的认识不断提高、医疗保健成本不断增加以及重磅药物专利到期数量的增加正在推动品牌非专利市场的成长。然而，有关药品核准和品管的严格监管要求，以及製造商之间激烈竞争导致的价格下降，可能会阻碍市场成长。然而，药物研究的进步使得生物等效产品的开发成为可能，为品牌非专利市场的成长创造了有利可图的机会。

主要市场统计
基准年[2023] 4323亿美元
预测年份 [2024] 4942.9亿美元
预测年份 [2030] 1,126,430 百万美元
复合年增长率（%） 14.66%

具有高付加价值的品牌非专利将因其付加的优势而广泛采用。

商品非专利是一种将现有学名药的可靠有效性与知名品牌的认可和声誉相结合的药物。这些产品具有学名药药和品牌药的优点，而且价格实惠且品质优良。药厂通常使用品牌学名药来进入竞争激烈的市场，为患者提供具有成本效益的替代品，同时保持对医疗工作者的安全性、有效性和可靠性的信心。付加产品是一个透过为消费者提供额外好处而区别于标准配方的类别。这些付加产品可结合多种活性成分以增强治疗效果，或采用创新剂型以增加便利性，例如缓释性或易于吞嚥的锭剂。在某些情况下，具有付加商品名的学名药，例如 Benitec A（奥美沙群和氨氯地平的组合药物）、Nifedical（硝苯地平）和Digitech（地高辛），可用于减少副作用或提高患者用药依从性。

药物类型高血压治疗中降血压药的高使用率

烷化剂是一类主要用于癌症治疗的药物，透过抑制 DNA 复製来限制癌细胞的生长和增殖，例如Cyclophosphamide、Melphalan和顺Cisplatin。抗忧郁症用于治疗各种型态的忧郁症和焦虑症，因为它们可以恢復大脑中神经传导物质的平衡，特别是血清素、去甲肾上腺素和多巴胺，因此不太常用抗忧郁症，其中包括Fluoxetine、文拉法辛和阿米替林。抗癫痫药物 (AED) 是用于预防或控制癫痫患者癫痫发作的药物。抗高血压药物可以降低高血压患者的血压，降低心臟病、中风和其他併发症的风险。抗精神病药物主要用于治疗双极性情感障碍和思觉失调症等精神障碍的症状。抗代谢药物是一组化疗药物，可抑制癌细胞中的细胞代谢和 DNA 合成，同时也能模仿 DNA 复製的基本组成部分并抑制参与这些过程的关键酵素。荷尔蒙药物用于治疗多种疾病，包括荷尔蒙失衡、内分泌失调和某些癌症。降血脂药物旨在减少血液中三酸甘油酯和胆固醇的升高，从而减少心臟病等心血管疾病的风险。

给药途径：口服给药因其作用时间长而被广泛采用。

口服途径因其方便、易于使用和非侵入性而成为最常见和优选的给药方法。患者口服锭剂、胶囊和液体型态的品牌学名药。此外，由于给药不需要特殊设备或医疗保健专业人员的监督，患者的依从性也得到了提高。肠外给药采用绕过消化器官系统并将药物直接输送到血液的方法。此途径包括皮下（SC）、肌肉内（IM）和静脉内（IV）注射和输注。此途径对于治疗需要快速缓解的病症或口服生物利用度低的药物特别有益。此外，它们通常比口服给药更昂贵，因为它们需要专门的设备和无菌製剂。局部给药涉及将品牌学名药直接涂布在皮肤或黏膜表面，例如乳膏、凝胶、软膏或经皮吸收贴片。此途径允许将药物局部输送到目标局部，同时最大限度地减少全身吸收和潜在的副作用。局部给药的优点包括与全身给药相比副作用风险降低以及易于使用，从而提高患者的依从性。然而，与局部给药相关的挑战包括药物渗透皮肤屏障的变异性以及应用部位的潜在刺激。

适应症 品牌非专利在胃肠道和神经系统疾病的使用迅速增加

品牌非专利对于提供止痛药、非类固醇发炎药 (NSAID) 和鸦片类药物的选择至关重要。品牌非专利为高血压、高血脂症、心臟衰竭和心律不整管理等心血管疾病提供了经济高效的选择。痤疮、真菌感染疾病、湿疹和干癣等皮肤病是全世界患者广泛关注的问题。品牌非专利提供了价格实惠的皮肤科治疗方法，例如皮质类固醇、类视色素A和抗真菌药物。发炎性肠道疾病(IBD)、胃食道逆流症 (GERD) 和大肠激躁症(IBS) 等胃肠道疾病可以透过质子帮浦阻断剂(PPI)、H2 受体拮抗剂和解痉药等经济有效的治疗非专利进行治疗。癫痫、帕金森氏症、多发性硬化症和偏头痛等神经系统疾病需要负担得起且有效的治疗方法，而品牌非专利药包括抗癫痫药 (AED)、多巴胺促效剂和单株抗体，我们正在帮助弥补这一差距。由于创新和分子标靶治疗的成本高昂，品牌非专利可能不可行，例如化疗、荷尔蒙疗法、免疫疗法和蛋白酪氨酸激酶抑制剂（TKI）为癌症治疗提供了具有成本效益的替代方案。学名药包括Celebrex（塞来昔布）胶囊、Vascepa（二十碳五烯酸）胶囊、Jublia（艾夫康唑）外用溶液、Asacol HD（美沙拉嗪）锭剂、Abraxane（白蛋白结合型紫杉醇）和Ampyra（达芬吡啶）锭剂都可以使用。

销售管道管道 不断发展的品牌非专利线上销售管道

品牌非专利药线下分销管道仍然是患者寻求药品的首选，这主要是因为其易于获取并能与医疗专业人员进行即时咨询。医院药局透过确保患者在治疗期间获得负担得起的药物，在提供优质医疗保健方面发挥重要作用。医院药局越来越喜欢品牌非专利，它们在价格实惠和品质保证之间取得了良好的平衡。这些药物是按照严格的指导方针生产的，并保持与专利药物相同的高功效。零售药局是消费者购买药品的主要场所，为寻求具有成本效益的替代品而不影响品质或功效的消费者创造了品牌非专利的巨大潜力。数位技术的快速进步为线上药局和电子商务平台成为药品分销的重要参与者铺平了道路。由于线上管道提供的便利性和成本节约（例如详细的产品资讯、有竞争力的价格和可靠的送货服务），消费者更喜欢在线购买药品，品牌非专利在该领域正在蓬勃发展。

区域洞察

由于强大的医疗基础设施和较高的人均医药支出，美洲地区的市场状况有利。政府努力提高人们对学名药的认识，这为品牌非专利带来了光明的成长前景。此外，大型製药企业对研发的投资导致新产品核准和创新疗法进入该市场。欧盟 (EU) 的品牌非专利产业呈现多样化的景象。随着欧盟国家医疗保健支出的增加以及各国政府对学名药实施优惠的定价政策，对具有成本效益的治疗方案的需求大幅增加。领先公司正在大力投资研发以开发新药，同时在新兴市场保持与低成本药物的竞争力。中东和非洲被认为是品牌非专利市场的成长机会，因为政府改善医疗基础设施和降低药品价格的努力是扩大市场机会的驱动力。由于研究和开发的活性化、政府的支持措施、对学名药的需求增加以及国际公司之间为开发创新治疗方法以满足全球需求而进行的合作激增，亚太地区的品牌非专利正在增长，这显示出巨大的发展潜力。

FPNV定位矩阵

FPNV 定位矩阵对于评估品牌非专利市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对品牌非专利市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估及资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行综合评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.品牌非专利市场的市场规模与预测为何？

2.品牌非专利市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.品牌非专利市场的技术趋势和法规结构是什么？

4.品牌非专利市场主要供应商的市场占有率为何？

5.进入品牌非专利市场的适当型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 需要使用学名药的慢性病的流行
      • 越来越多的重磅药物专利到期以及对具有成本效益的替代品的需求
    • 抑制因素
      • 对品牌学名药品质差异的担忧
    • 机会
      • 透过新的生物等效性研究和市场参与者，努力扩大品牌非专利业务
    • 任务
      • 与诉讼问题和品牌药价格下跌相关的问题
  • 市场区隔分析
    • 产品：大量采用付加品牌非专利可带来额外好处
    • 药物类型： 抗高血压药物常用于治疗高血压。
    • 给药途径：口服给药因其作用时间长而被广泛采用。
    • 适应症：品牌非专利在胃肠道和神经系统疾病的使用激增
    • 分销管道：品牌非专利线上分销管道的演变
  • 市场趋势分析
    • 美洲品牌非专利的结构良好的标准的可用性
    • 亚太地区政府的支持措施和对平价品牌学名药不断增长的需求
    • 专注于扩大欧洲、中东和非洲地区品牌非专利地理覆盖范围的知名製药公司的存在
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章 品牌非专利市场：副产品

  • 产品名称学名药
  • 付加价值

第七章 品牌非专利药的类型

  • 烷化剂
  • 抗忧郁症
  • 抗癫痫药
  • 抗高血压
  • 抗精神病药
  • 抗代谢物
  • 荷尔蒙
  • 降血脂药

第八章 品牌非专利市场：依管理途径

  • 口服
  • 胃肠外的
  • 话题

第九章以适应症分類的品牌非专利市场

  • 急性和慢性疼痛
  • 心血管疾病
  • 皮肤病
  • 消化系统疾病
  • 神经系统疾病
  • 肿瘤学

第 10 章 品牌非专利市场：按分销管道

  • 离线
  • 在线的

第十一章 美洲品牌非专利市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太品牌非专利市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的品牌非专利市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Vyvanse非专利获 FDA核准
    • 药联会与学名药协会更新学名药定价协议
    • Amneal 推出经批准的非专利Xyrem（奥昔巴特钠）并获得 FDA核准其五种复合非专利
    • Ajanta Pharma 旨在扩大快速成长的亚洲和非洲地区的业务
    • 雷迪博士进军国内市场学名药业务
    • Sun Pharma 推出辉瑞重磅抗癌药物的非专利药
    • Zentiva 完成西班牙 Tiromed 关键产品的收购
    • Cipla推出“Easy Lux L”，一种缓解便秘的无糖口服乳液泻药
    • ProCaps Group 从 Advent International 收购 Grupo Somar

第15章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-A26E0E57422E

[194 Pages Report] The Branded Generics Market size was estimated at USD 432.30 billion in 2023 and expected to reach USD 494.29 billion in 2024, at a CAGR 14.66% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts. Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

KEY MARKET STATISTICS
Base Year [2023] USD 432.30 billion
Estimated Year [2024] USD 494.29 billion
Forecast Year [2030] USD 1,126.43 billion
CAGR (%) 14.66%

Product: Significant adoption of value-added branded generics due to their additional advantages

Ttrade-named generics are the pharmaceutical product that combines the trusted efficacy of an established generic drug with the recognition and reputation of a well-known brand name. These products offer the benefits of both generic and branded medicines, with high quality at an affordable price. Pharmaceutical manufacturers commonly use trade-named generics to penetrate competitive markets, providing patients and healthcare professionals with cost-effective alternatives that maintain trust in safety, effectiveness, and reliability. Value-added offerings represent a distinct category that differentiates itself from standard formulations by bringing additional benefits to the consumer. These value-added products may combine multiple active ingredients for enhanced therapeutic effects or adopt innovative dosage forms for improved convenience, such as extended-release formulations or easy-to-swallow tablets. In some cases, value-added trade-named generics can also include drugs reformulated to reduce side effects or improve patient adherence, such as Benitek A (Olmesatran in combination with Amlodipine), Nifedical (nifedipine), and Digitek (digoxin).

Drug Type: High usage of anti-hypertensive for treating high blood pressure

Alkylating agents are a class of drugs primarily used in cancer treatment, and they work by inhibiting DNA replication restricting the growth and multiplication of cancer cells, such as cyclophosphamide, melphalan, and cisplatin. Anti-depressant medications are used to treat various forms of depression and anxiety disorders as they restore the balance of neurotransmitters within the brain, particularly serotonin, norepinephrine, and dopamine, and commonly prescribed anti-depressants include fluoxetine, venlafaxine, and amitriptyline. Anti-epileptic drugs (AEDs) are medications designed to prevent or control epileptic seizures in individuals diagnosed with epilepsy. Anti-hypertensive medications lower blood pressure in individuals with hypertension, reducing the risk of heart disease, stroke, and other complications. Antipsychotic medications are primarily used to manage symptoms of psychotic diseases such as bipolar disorder and schizophrenia. Antimetabolites are a group of chemotherapeutic agents that interfere with cellular metabolism and DNA synthesis in cancer cells while they mimic essential building blocks for DNA replication or inhibit critical enzymes involved in these processes. Hormone-based medications are used in various medical conditions, including hormone imbalances, endocrine disorders, and certain cancers. Lipid-lowering medications are designed to reduce elevated levels of triglyceride and cholesterol in the blood, lowering the chance of cardiovascular disorders such as heart attacks.

Route of Administration: Wide adoption of oral route due to their longer duration of action

The oral route is the most common and preferred method of drug administration due to its convenience, ease of use, and non-invasive nature. Branded generic medications in forms such as tablets, capsules, or liquids are taken orally by the patient. Additionally, they provide higher patient compliance as they do not require specialized equipment or healthcare professional oversight for administration. Parenteral administration involves delivering drugs directly into the bloodstream through means that bypass the digestive system. This route includes subcutaneous (SC), intramuscular (IM), and intravenous (IV) injections and infusions. This route is particularly beneficial when treating conditions requiring quick relief or if a drug has poor oral bioavailability. Additionally, it is generally more expensive than oral administration due to specialized equipment and sterile preparation requirements. Topical administration involves applying branded generic medications directly onto the skin or mucosal surfaces, such as creams, gels, ointments, or transdermal patches. This route allows localized drug delivery to the target site while minimizing systemic absorption and potential side effects. Advantages of topical administration include reduced risk of adverse reactions compared to systemic routes and improved patient compliance due to ease of use. However, challenges associated with topical drug delivery include variability in drug penetration through the skin barrier and the potential for irritation at the application site.

Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases

Branded generics are crucial in providing options for analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. Branded generics offer cost-effective alternatives for cardiovascular diseases such as managing hypertension, hyperlipidemia, heart failure, and arrhythmias. Skin conditions such as acne, fungal infections, eczema, and psoriasis are widespread concerns among patients globally, and branded generics provide affordable access to dermatological treatments, including corticosteroids, retinoids, and antifungal agents. Gastrointestinal diseases such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) require long-term management with medications that are fulfilled by branded generics that offer cost-effective therapies, including proton-pump inhibitors (PPIs), H2 receptor antagonists, and antispasmodics. Neurological disorders such as epilepsy, Parkinson's disease, multiple sclerosis, and migraines demand effective treatments at affordable prices, and branded generics help bridge this gap with anti-epileptic drugs (AEDs), dopaminergic agents, and monoclonal antibodies. Branded generics provide cost-effective alternatives for chemotherapy drugs, hormone therapies, immunotherapies, and tyrosine kinase inhibitors (TKIs) for cancer treatment, as they are perceived as unattainable due to the high costs associated with innovative therapies and targeted agents. Generic versions of Celebrex (celecoxib) capsules, Vascepa (icosapent ethyl) capsules, Jublia (efinaconazole) topical solution, Asacol HD (mesalamine) tablets, Abraxane (nab-paclitaxel), Ampyra (dalfampridine) extended-release tablets are available for treating several diseases.

Distribution Channel: Evolving online distribution channels for branded generics

The offline distribution channel for branded generics remains the first preference for patients seeking medications, primarily due to ease of access and real-time consultation with healthcare professionals. Hospital pharmacies play a vital role in providing quality healthcare by ensuring patients have access to affordable medications during treatment. Hospital pharmacies increasingly favor branded generics as they balance affordability and quality assurance. These drugs are manufactured following strict guidelines and maintain a high efficacy comparable to their patented counterparts. Retail pharmacies serve as a primary source of medications among the general public and create an enormous potential for branded generics as consumers seek cost-effective alternatives without compromising on quality or efficacy. The rapid advancement of digital technologies has paved the way for online pharmacies and eCommerce platforms to emerge as significant players in the pharmaceutical distribution landscape. Branded generics have observed substantial growth in this space due to the convenience and cost savings these online channels provide due to its accessibility of detailed product information, competitive pricing, and reliable delivery services that have led consumers to prefer purchasing their medications online.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector. There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Branded Generics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Branded Generics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Trade Named Generics
    • Value-Added
  • Drug Type
    • Alkylating Agents
    • Anti-depressants
    • Anti-epileptics
    • Anti-hypertensive
    • Anti-psychotics
    • Antimetabolites
    • Hormones
    • Lipid Lowering Drugs
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Indication
    • Acute & Chronic Pain
    • Cardiovascular Diseases
    • Dermatological Diseases
    • Gastrointestinal Diseases
    • Neurological Diseases
    • Oncology
  • Distribution Channel
    • Offline
      • Hospital Pharmacy
      • Retail Pharmacy
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Branded Generics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Branded Generics Market?

3. What are the technology trends and regulatory frameworks in the Branded Generics Market?

4. What is the market share of the leading vendors in the Branded Generics Market?

5. Which modes and strategic moves are suitable for entering the Branded Generics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
      • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with quality variations in branded generic medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
    • 5.1.4. Challenges
      • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
    • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
    • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
    • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
    • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
  • 5.3. Market Trend Analysis
    • 5.3.1. Availability of well-structured standards for branded generics in the Americas
    • 5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
    • 5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Branded Generics Market, by Product

  • 6.1. Introduction
  • 6.2. Trade Named Generics
  • 6.3. Value-Added

7. Branded Generics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Alkylating Agents
  • 7.3. Anti-depressants
  • 7.4. Anti-epileptics
  • 7.5. Anti-hypertensive
  • 7.6. Anti-psychotics
  • 7.7. Antimetabolites
  • 7.8. Hormones
  • 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Branded Generics Market, by Indication

  • 9.1. Introduction
  • 9.2. Acute & Chronic Pain
  • 9.3. Cardiovascular Diseases
  • 9.4. Dermatological Diseases
  • 9.5. Gastrointestinal Diseases
  • 9.6. Neurological Diseases
  • 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
  • 10.3. Online

11. Americas Branded Generics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Branded Generics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Vyvanse Generics Approved by FDA
    • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
    • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
    • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
    • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
    • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
    • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
    • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BRANDED GENERICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 313. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 325. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 326. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 337. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 338. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 349. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 350. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTR